DF/HCC Ovarian Cancer SPORE - Seeking Project Ideas

Application Deadline: Please submit the LOI by June 30th 2025 and any questions to: Ursula Matulonis, MD Dana-Farber Cancer Institute
Email: ursula_matulonis@dfci.harvard.edu

Click here to learn more



This series offers a multidisciplinary HMS CME conference open to DF/HCC institutions (BWH, BIDMC, BCH, HSPH, HMS and MGH), and remote participation through Zoom. The series hosts renowned local, national and international speakers presenting impactful findings in ovarian cancer. Note: there will be no recordings for these talks, and all talks begin at 3PM EST, unless mentioned otherwise.


Learn more or attend this series

DF/HCC SPORE in Ovarian Cancer

The central focus of the Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Ovarian Cancer is the understanding and overcoming mechanisms of primary and acquired treatment resistance in ovarian cancer.  Our SPORE seeks to make translational progress in understanding resistance mechanisms that will lead to meaningful and improved outcomes of women with newly diagnosed ovarian cancer and those with relapsed ovarian cancer. The DF/HCC SPORE in Ovarian Cancer includes DF/HCC researchers from the Dana-Farber Cancer Institute, Massachusetts General Hospital (MGH), Brigham and Women’s Hospital, Beth Israel Deaconess Hospital, and Harvard Medical School (HMS). In addition, this SPORE includes investigators from outside of DF/HCC who are international experts in their fields, and they include researchers from the Massachusetts Institute of Technology (MIT) and the Broad Institute.  We also have incorporated experienced patient advocates into this SPORE’s advisory structures.

The DF/HCC Ovarian Cancer SPORE features three projects,three cores, a developmental research program and a career enhancement program.

If you are interested in becoming involved in the Ovarian Cancer SPORE program, please contact: